Investigation of the Clinical Efficacy and Safety of Algan Products, a Herbal Hemostatic Agent, in Open Heart Surgery.
Objective: Stopping bleeding that occurs during surgical operations or other emergencies is very important to prevent negative consequences by reducing blood loss. The aim of this study is to investigate the hemostatic effectiveness and safety of the polysaccharide-based Algan hemostatic agent, a herbal product, in open heart surgery.
Material and Methods: 140 patients who underwent coronary surgery were included in this study. The patients were randomly divided into 4 groups, each consisting of 35 patients. The 1st group was determined as the Algan Powder, the 2nd group as the Algan Sponge, the 3rd group as the Algan liquid, and the 4th group as the control group in which only traditional haemostatic methods were used. Algan hemostatic agent was used to control bleeding in coronary anastomoses and perivascular fatty tissue in the myocardium.
Results: On the first postoperative day, the average drainage was 363 ml in Algan powder, 442 ml in Algan sponge, 545 ml in Algan liquid, and 997 ml in the control group. These results were found to be statistically significant in favor of all three different versions of Algan (p < 0.039). Additionally, as an important difference, the treatment group was found to be statistically more significant than Algan’s groups in terms of the rate of erythrocyte suspension use (p < 0.004).
Conclusion: It was observed that powder, sponge, and liquid forms of Algan hemostatic agent can be used safely and effectively as a hemostatic agent in open heart surgery.
Keywords: Algan hemostatic agent, Open heart surgery, Bleeding
